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We investigated the prognostic significance of circulating breast cancer cells in peripheral blood detected by quantitative RT–PCR of
marker genes in patients with advanced breast cancer. Blood samples from 94 breast cancer patients with metastatic disease (M1)
were examined for circulating tumour cells by studying the mRNA expression of CK19, p1B, PS2 and EGP2 by real-time PCR. Using a
score function, developed for predicting circulating tumour cells by quadratic discriminant analysis (QDA), the four expression levels
were combined into a single discriminant value. Tumour cells were present in 24 out of 94 (31%) of the patients. In 77% (72 out of
94) of the patients distant metastatic disease was localised in the bone. In 36% (26 out of 72) of the patients with bone metastases at
the time of blood sampling, a positive QDA for the four genes was found, in contrast to only 14% (three out of 22) without bone
involvement. Overall survival rates by Kaplan–Meier revealed no prognostic effect for the presence of bone metastases (P¼0.93).
However, patients with a positive QDA value did have a progression-free survival at 1 year of 3% and overall survival at 2 years of
17%, against 22 and 36% for patients with a negative QDA value (P¼0.015 and 0.0053, respectively). Breast cancer patients with
metastatic disease have a significantly worse progression-free and overall survival when circulating tumour cells can be detected in
their peripheral blood.
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Metastases in breast cancer may arise through either lymphatic
spread or through hematogenous dissemination. While the local
treatment of breast cancer is quite successful and modern
treatment can adequately deal with local lymph node metastases,
a substantial proportion of breast cancer patients ultimately die
from metastases to distant organs or tissues. Micrometastatic
disease may be cured by adjuvant systemic therapy and the ability
to detect it reliably would thus be a significant advance. We have
recently shown that the tendency for hematogenous spread can
already be shown in small tumours, using messenger-RNA
(mRNA) expression profiling (van ’t Veer et al, 2002). In addition,
we and others have developed immunological and RNA-based
methods to detect circulating tumour cells in blood, bone marrow
and other nonbreast tissues (Lambrechts et al, 1998). There is
evidence that the presence of epithelial cells in the bone marrow of
patients with early breast cancer correlates with prognosis (Braun
et al, 2000). Antibody-based methods to detect these occult tumour
cells have, however, not gained widespread clinical use because of
significant numbers of false-positive results (Lambrechts et al,
1998, 1999).
RNA-based methods have been used to detect the presence of
mRNA species in RNA isolations from peripheral blood mono-
nuclear cells that are characteristic of epithelial cells and that may
originate from circulating tumour cells. The main problem of
RNA-based assays continues to be the almost universally present
background signal (Traweek et al, 1993; Datta et al, 1994; Burchill
et al, 1995; Krismann et al, 1995; Fields et al, 1996; Moscinski et al,
1996; Mapara et al, 1997; Zippelius et al, 1997). We have recently
developed a method that overcomes these problems by making use
of two relatively recent developments. First, a truly quantitative
PCR has become available, which is known as ‘real-time PCR’
(Bieche et al, 1999). Second, we have selected mRNA species using
SAGE that are not present in peripheral blood RNA isolates or in
bone marrow cells of healthy volunteers, but that are highly
expressed in most breast cancers (Bosma et al, 2002). A panel of
four marker genes (p1B, PS2, CK19 and EGP2) was used to detect
circulating tumour cells in the peripheral blood of breast cancer
patients; peripheral blood samples of healthy females were used as
controls. Using a quadratic discriminant analysis (QDA), a score
function based on the mRNA levels of the four genes was derived
which, when positive, predicts the presence of circulating tumour
cells (Bosma et al, 2002). This assay yields positive results in
roughly 30% of the patients receiving treatment for advanced
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more frequent in patients with bone metastases and is furthermore
associated with a reduced survival.
MATERIAL AND METHODS
Patients
This study is based on the same patient series as reported earlier
(Bosma et al, 2002). One hundred and three patients with
advanced breast cancer, who were under treatment at the
outpatient clinic of the Netherlands Cancer Institute, were asked
to participate in the study. No other selection criteria were applied.
Patients receiving hormonal treatment, intravenous administration
of bisphosphanates or who were undergoing chemotherapy (or any
combination) were eligible. Blood samples were collected during a
routine follow-up visit in the Netherlands Cancer Institute/Antoni
van Leeuwenhoek hospital between 1997 and 1998. A written
informed consent was obtained from all the patients and the study
was approved by the institute’s protocol review committee.
Patient characteristics and follow-up information were extracted
from the clinical charts. These included demographical data, the
date of diagnosis of breast cancer, performance status, sites of
metastatic disease, haemoglobin, white blood cell (WBC) count,
platelets, LDH, CEA and CA15.3. In addition, the presence of either
progressive or responding disease at the time of blood sampling
was noted. The dates for first treatment progression and death
were also extracted from the charts.
For this study, nine of the 103 patients had to be excluded
because they were not under further treatment at the NKI and had
been lost in follow-up, leaving 94 patients for the analysis.
Statistics
The QDA score function as defined earlier (Bosma et al, 2002) was
calculated from the expression levels of the four marker genes p1B,
PS2, CK19 and EGP2. A threshold was set that gave the maximum
number of correctly classified patients in the breast cancer group
(sensitivity) at zero misclassified normal controls (specificity was
set to 100%) (Bosma et al, 2002).
Survival was calculated from the date of blood sample to the
date of last follow-up (censored) or date of death from any cause
(event). Progression-free survival was calculated from the date of
blood sampling to the date of last follow-up (censored) or date of
progression/death from any cause (event). Patients, in whom
evidence of progression was present at the date of blood sample,
were assigned a progression-free survival of zero months.
(Progression-free) survival curves were calculated using the
method of Kaplan–Meier and compared using the likelihood ratio
test based on proportional hazard regression analysis.
Proportional-hazard regression analysis was used to adjust the
association between QDA and survival or progression-free survival
for confounding by any other metastastic site (liver, bone, lung or
other sites) or form of treatment (chemotherapy, hormonal
therapy or both).
The median follow-up from the date of blood sampling for all
the 94 patients included is 15 months (range 0.4 – 53) and for the
17 patients still alive 45 months (12 – 53).
Results
Ninety-four breast cancer patients with metastatic disease were
studied for the prognostic significance of positive breast cancer
marker gene expression in their peripheral blood. All the patients
had metastatic disease, most of them had metastases at several
locations. Twelve patients did not receive any systemic treatment
at the time of blood sampling, 36 patients received chemotherapy,
39 hormonal treatment and seven received both (patient
characteristics, see Table 1). The circulating breast tumour cell
assay by real-time PCR quantification for the four marker genes
p1B, PS2, CK19 and EGP2 revealed that 29 out of 94 patients had a
positive discriminant value for circulating breast tumour cells, as
reported earlier (Bosma et al, 2002).
A positive test for circulating tumour cells was (almost
exclusively) found in patients with bone metastases (Figure 1).
Twenty-six of the 72 patients (36%) with bone metastases had a
positive QDA value, versus three of the 22 patients (13.6%) without
bone metastases (w
2 test P¼0.037). A positive QDA value was also
associated with liver metastases. Thirteen of the 27 patients (48%)
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Figure 1 Twenty-six of the 72 patients with bone metastases (BM+)
had a positive QDA value against three of the 22 patients without bone
involvement (BM )( w
2 test P¼0.037). We previously defined a cutoff
value of zero QDA arbitrary units on the QDA score to set the specificity
to 100% (Bosma et al, 2002).
Table 1 Clinical characteristics of 94 breast cancer patients with M1
disease
No. of patients (n=94)
Characteristic No. %
Metastases
a
Bone metastasis 72 77
Liver metastasis 27 29
Metastases at other sites 67 71
Systemic treatment
a
Chemotherapy 36 38
Hormonal treatment 39 42
Chemo- and hormonal therapy 7 7
No treatment 12 13
Progressive disease
a 31 33
Age at initial diagnosis (year) 48.7 (28 – 80)
Age at blood sampling (year) 54.1 (31 – 82)
Interval initial diagnosis–blood (year) 5.4 (0.03 – 21.6)
aAt the time of blood sampling.
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patients (24%) without liver metastases (w
2 test P¼0.022, data not
shown). Logistic regression analysis revealed that these associa-
tions are independent of each other. The results of the circulating
breast cancer cell assay were further correlated with each of the
quantitative data extracted from the patient charts. There was no
apparent relation with age, the time since primary diagnosis, levels
of LDH or tumour markers, WBC counts or platelet count or with
the presence of disease progression at the time of sampling.
Thirty-three percent of the patients had progressive disease at
the date of the blood sampling (31 out of 94). After 6 months, 33%
were still alive without progression, after 12 months 16%, after 2
years 10% and after 4 years 5%. There is evidence (P¼0.015) that
progression-free survival is worse for patients with a positive QDA
value from the four marker genes (Figure 2). The presence of
circulating tumour cell mRNA in the peripheral blood is clearly
associated with a worse overall survival (P¼0.0053, Figure 3). The
median survival of patients with a positive test was 6 months, while
the median survival of patients with a negative test was 18 months.
No difference between positive and negative QDA patients was
found regarding the interval between diagnosis and blood drawing
(t-test: P¼0.71).
The poor prognosis observed in patients with circulating
tumour cells is not simply because of the more frequent presence
of bone metastases: as expected, bone metastases were not a
particularly negative prognostic feature for breast cancer patients
with stage IV disease (Figure 4, P¼0.93).
DISCUSSION
Many methods have been evaluated to reliably detect circulating
tumour cells in breast cancer and in other solid malignancies, with
the purpose to serve as prognostic marker. All are either based on
the presence of epithelial or tumour-specific antigens in circulating
cells or are based on the demonstration of RNA-species in
peripheral blood cells that indicate the presence of epithelial or
tumour cells. However, assays of both types have been associated
with false-positive results.
Recently, the real-time PCR provided a major step forward in
the power to quantitatively analyse low abundance RNA species
(Bieche et al, 1999) and may ensure the specificity that is required
for a clinically useful test. Using this method, we have recently
described the identification of four marker genes for the detection
of occult tumour cells in breast cancer patients and determined
how the respective expression levels can be combined by QDA to
allow the avoidance of false-positive results (Bosma et al, 2002). In
the peripheral blood of a series of patients with metastatic breast
cancer who were receiving systemic treatment but were otherwise
unselected, 30% of the patients revealed a positive QDA. Here we
show that this positive QDA value is associated with the presence
of bone metastases and predicts a significantly shortened survival,
whereas bone metastases do not.
Our results show that the test has a clear biological correlate and
may truly represent the presence of circulating breast cancer cells.
It is tempting to speculate that particularly tumour cells lodging in
the bone marrow, that are responsible for bone metastases, may
spill over into the blood and circulate through the body. It could
also be that our patients with bone metastases and liver metastases
had a larger total tumour volume than the other patients. It is not
possible to determine this retrospectively. In fact, a multivariate
analysis for survival that did take the site of metastasis and form of
therapy into account, resulted in an increase of the P-value for the
QDA score for survival to P¼0.094, and was thus not significant
(data not shown). Our test for circulating tumour cells was,
however, not designed to predict progression-free survival, but
rather to establish a biological correlate.
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Figure 2 Kaplan–Meier curves for progression-free survival in patients
with or without a positive test for circulating tumour cells (likelihood ratio
test; P¼0.015). Patients at risk at each time point (years) are indicated for
‘QDA positive’ (black) and ‘QDA negative’ (grey) patients.
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Figure 3 Kaplan–Meier curves for overall survival of patients with or
without circulating tumour cells (likelihood ratio test; P¼0.0053). Patients
at risk at each time point (years) are indicated for ‘QDA positive’ (black)
and ‘QDA negative’ (grey) patients.
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Figure 4 Kaplan–Meier curves for overall survival with respect to the
presence of bone metastases. No prognostic value was found for the
presence of bone metastases (likelihood ratio test; P¼0.93). Patients at risk
at each time point (years) are indicated for ‘bone metastasis’ (black) and ‘no
bone metastasis’ (grey) patients.
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between the date of the first metastasis detected and the time, at
which the blood sample was drawn, influenced the QDA value
(Figure 5). For 86 patients, the time of the detection of the first
metastasis was available. In the interval of 6 months between the
date of the first metastasis and blood sampling, 29% (eight out of
28) of the patients have a positive QDA value, compared with 29%
(nine out of 31) in the subsequent interval of one-and-a-half years
and 37% (10 out of 27) in the interval between 2 and 12 years. This
shows that the positivity for the four marker genes is independent
from the time when the blood sample is drawn in a metastasized
patient. Thus, the detection of circulating tumour cells is not
correlated with initial time or interval after the diagnosis of
metastatic disease.
At present, it is not clear whether patients with a positive
circulating tumour cell test would benefit from different, maybe
more intensive treatment. The presence of micrometastatic disease
and of circulating tumour cells may be of much greater importance
in the management of patients with early (stages I – III) breast
cancer. In this situation, prognostic information is essential to
appropriately select patients for adjuvant therapy, such as
hormone treatment and/or chemotherapy. We have recently
shown, using expression profiling that even in early, lymph
node-negative tumours, a group of patients can be identified who
have a poor prognosis (van ’t Veer et al, 2002). A reliable
circulating tumour cell assay could help in the identification of
additional mRNA-expression patterns that are associated with this
unfavourable biologic property and could also provide indepen-
dent information further narrowing down the specific risk
category.
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Figure 5 Distribution of the QDA value with respect to the interval
between the detection of the first metastasis and the time of blood
sampling for 86 breast cancer patients.
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